Aspirin and the Risk of Hepatocellular Carcinoma Development in Patients with Alcoholic Cirrhosis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Mar 3

PMID 32118712

Citations 16

Authors

Sangdeok Shin

Sang Hoon Lee

Minjong Lee

Ji Hyun Kim

Wongu Lee

Hyun Woo Lee

Min Soo Park

Seungwoo Park

Tae Suk Kim

Dae Hee Choi

Affiliations

Soon will be listed here.

Abstract

Aspirin therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. However, it is unclear whether aspirin therapy lowers the risk of HCC in patients with alcoholic cirrhosis.A retrospective analysis of data from 949 consecutive patients with alcoholic cirrhosis who abstained from alcoholic drinking was performed. The primary and secondary outcomes were development of HCC and gastrointestinal bleeding events, respectively. Risk was compared between patients with aspirin treatment and patients who were not treated (non-aspirin group) using a time-varying Cox proportional hazards model for total population and propensity score-matching analysis.The aspirin group included 224 patients and the non-aspirin group had 725 patients. During the study period of median duration of 3.1 years, 133 patients (13.6%) developed HCC. In time-varying Cox proportional analyses, the aspirin group showed a significantly lower risk of HCC (adjusted hazard ratio [aHR]: 0.13; 95% confidence interval [CI]: 0.08-0.21; P < .001). In propensity score-matched pairs, aspirin therapy significantly reduced the risk of HCC (aHR: 0.14; 95% CI: 0.09-0.22; P < .001). In bleeding risk, treatment with aspirin alone was not significantly associated with a higher bleeding risk (aHR: 0.81; 95% CI: 0.45-1.44; P = .46).Aspirin therapy was associated with the lower risk of HCC in patients with alcoholic cirrhosis.

Citing Articles

Current and emerging strategies for the prevention of hepatocellular carcinoma.

Yeo Y, Abdelmalek M, Khan S, Moylan C, Rodriquez L, Villanueva A Nat Rev Gastroenterol Hepatol. 2024; 22(3):173-190.

PMID: 39653784 DOI: 10.1038/s41575-024-01021-z.

Prognostic impact of aspirin in patients with hepatocellular carcinoma after liver resection: propensity-score-matched analysis.

Matsumoto T, Kitano Y, Imai K, Ogawa D, Yumoto S, Takematsu T Int J Clin Oncol. 2024; 30(1):92-98.

PMID: 39438421 DOI: 10.1007/s10147-024-02646-5.

Association between antithrombotic agents use and hepatocellular carcinoma risk: a two-sample mendelian randomization analysis.

Yang F, Li O, Gao B, Chen Z, Li B, He J J Cancer Res Clin Oncol. 2024; 150(10):470.

PMID: 39436427 PMC: 11496351. DOI: 10.1007/s00432-024-05960-7.

Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial.

Lu C, Jiang Y, Feng J, Wang L, Wei X, Zhou B Heliyon. 2023; 9(9):e20015.

PMID: 37810112 PMC: 10559736. DOI: 10.1016/j.heliyon.2023.e20015.

The Effect of Aspirin Use on Incident Hepatocellular Carcinoma-An Updated Systematic Review and Meta-Analysis.

Abdelmalak J, Tan N, Con D, Eslick G, Majeed A, Kemp W Cancers (Basel). 2023; 15(13).

PMID: 37444628 PMC: 10341252. DOI: 10.3390/cancers15133518.

References

Maini M, Schurich A . Platelets harness the immune response to drive liver cancer. Proc Natl Acad Sci U S A. 2012; 109(32):12840-1. PMC: 3420167. DOI: 10.1073/pnas.1210296109. View

Gao B, Bataller R . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141(5):1572-85. PMC: 3214974. DOI: 10.1053/j.gastro.2011.09.002. View

Tarantino G, Citro V, Conca P, Riccio A, Tarantino M, Capone D . What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?. BMC Gastroenterol. 2009; 9:89. PMC: 2785828. DOI: 10.1186/1471-230X-9-89. View

Fujiwara N, Singal A, Hoshida Y . Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma. Hepatology. 2019; 70(6):2216-2217. PMC: 6885093. DOI: 10.1002/hep.30813. View

Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F . Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A. 2012; 109(32):E2165-72. PMC: 3420192. DOI: 10.1073/pnas.1209182109. View

Sahasrabuddhe V, Gunja M, Graubard B, Trabert B, Schwartz L, Park Y . Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012; 104(23):1808-14. PMC: 3514167. DOI: 10.1093/jnci/djs452. View

Lee M, Chung G, Lee J, Oh S, Nam J, Chang Y . Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology. 2017; 66(5):1556-1569. DOI: 10.1002/hep.29318. View

Wang P, Kang D, Cao W, Wang Y, Liu Z . Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2011; 28(2):109-22. DOI: 10.1002/dmrr.1291. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

10.

Iannacone M, Sitia G, Isogawa M, Marchese P, Castro M, Lowenstein P . Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med. 2005; 11(11):1167-9. PMC: 2908083. DOI: 10.1038/nm1317. View

11.

Sitia G, Iannacone M, Guidotti L . Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013; 59(5):1135-8. DOI: 10.1016/j.jhep.2013.05.040. View

12.

Jiang Z, Feldbrugge L, Tapper E, Popov Y, Ghaziani T, Afdhal N . Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2016; 43(6):734-43. DOI: 10.1111/apt.13515. View

13.

Assy N, Hussein O, Khalil A, Luder A, Szvalb S, Paizi M . The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci. 2007; 52(5):1187-93. DOI: 10.1007/s10620-006-9595-1. View

14.

Shintani A, Girard T, Eden S, Arbogast P, Moons K, Wesley Ely E . Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med. 2009; 37(11):2939-45. PMC: 3365557. DOI: 10.1097/CCM.0b013e3181b7fbbb. View

15.

Yu S . A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016; 22(1):7-17. PMC: 4825164. DOI: 10.3350/cmh.2016.22.1.7. View

16.

Kim D, Kim S, Ahn S, Park J, Lee J, Park Y . Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci. 2008; 54(8):1758-63. DOI: 10.1007/s10620-008-0541-2. View

17.

Jung K, Kim S, Ahn S, Park Y, Kim D, Park J . Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011; 53(3):885-94. DOI: 10.1002/hep.24121. View

18.

Rehm J, Samokhvalov A, Shield K . Global burden of alcoholic liver diseases. J Hepatol. 2013; 59(1):160-8. DOI: 10.1016/j.jhep.2013.03.007. View

19.

. The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017. Hepatology. 2017; 66(S1):1-1185. DOI: 10.1002/hep.29500. View

20.

Tarantino G, Citro V, Esposito P, Giaquinto S, de Leone A, Milan G . Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins. BMC Gastroenterol. 2009; 9:21. PMC: 2662872. DOI: 10.1186/1471-230X-9-21. View